Safety and tolerability of xanomeline and trospium chloride in schizophrenia: Pooled results from the 5-week, randomized, double-blind, placebo-controlled …
1. 请及时下载文件确认是否正确, 系统将在 2025-08-24 17:03:39 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.4088/JCP.24m15497
文献链接: https://pubmed.ncbi.nlm.nih.gov/40047530/
其他信息:
I Kaul, A Claxton, S Sawchak, C Sauder…
J Clin …, 2025
psychiatrist.com
Objective: To further characterize the safety and tolerability of oral xanomeline and trospium chloride in the treatment of people with schizophrenia experiencing acute psychosis. Methods: Pooled analyses were performed on safety data from the 5-week, randomized, double-blind, placebo-controlled, inpatient EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials of xanomeline/trospium in adults with schizophrenia with a recent worsening of psychosis requiring hospitalization. Adverse events (AEs) including extrapyramidal motor …
